Join Growin Stock Community!

Aquestive therapeutics, inc.AQST.US Overview

US StockHealthcare
(No presentation for AQST)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AQST AI Insights

AQST Overall Performance

AQST AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AQST Recent Performance

2.88%

Aquestive therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

AQST PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AQST Key Information

AQST Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AQST Profile

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Price of AQST

AQST FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AQST Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.69
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11.25
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
60.28%
Net Margin
-158.95%
Revenue Growth (YoY)
-26.32%
Profit Growth (YoY)
-36.00%
3-Year Revenue Growth
3.76%
3-Year Profit Growth
6.68%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.69
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11.25
PB Ratio
-
Price-to-FCF
-
Gross Margin
60.28%
Net Margin
-158.95%
Revenue Growth (YoY)
-26.32%
Profit Growth (YoY)
-36.00%
3-Year Revenue Growth
3.76%
3-Year Profit Growth
6.68%

  • When is AQST's latest earnings report released?

    The most recent financial report for Aquestive therapeutics, inc. (AQST) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AQST's short-term business performance and financial health. For the latest updates on AQST's earnings releases, visit this page regularly.

  • What is the operating profit of AQST?

    According to the latest financial report, Aquestive therapeutics, inc. (AQST) reported an Operating Profit of -11.48M with an Operating Margin of -89.63% this period, representing a decline of 38.47% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AQST's revenue growth?

    In the latest financial report, Aquestive therapeutics, inc. (AQST) announced revenue of 12.81M, with a Year-Over-Year growth rate of -5.43%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does AQST have?

    As of the end of the reporting period, Aquestive therapeutics, inc. (AQST) had total debt of 128.3M, with a debt ratio of 0.78. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AQST have?

    At the end of the period, Aquestive therapeutics, inc. (AQST) held Total Cash and Cash Equivalents of 129.06M, accounting for 0.79 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AQST go with three margins increasing?

    In the latest report, Aquestive therapeutics, inc. (AQST) did not achieve the “three margins increasing” benchmark, with a gross margin of 64.8%%, operating margin of -89.63%%, and net margin of -120.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AQST's profit trajectory and future growth potential.

  • Is AQST's EPS continuing to grow?

    According to the past four quarterly reports, Aquestive therapeutics, inc. (AQST)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AQST?

    Aquestive therapeutics, inc. (AQST)'s Free Cash Flow (FCF) for the period is -12.88M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 7.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.